Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation

Next Previous
Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegipanermin (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MINDFuL
  • Sponsors INmune Bio

Most Recent Events

  • 26 Jun 2025 According to an INmune Bio media release, company will host a conference call on Monday, June 30 beginning at 8 am EDT to present top line data from the Phase 2 MINDFuL trial in early Alzheimers Disease.
  • 04 Apr 2025 This MR (9439348) focuses on the baseline characteristics of the study participants. It describes the state of the patients before they began receiving the trial drug (XPro™) or placebo. It does not provide results regarding the efficacy of the drug itself. Those results would come from analyzing the changes in cognitive scores (EMACC, etc.) after the 23-week treatment period.
  • 01 Apr 2025 According to an INmune Bio media release, company is presenting baseline demographics and disease characteristics a poster at the annual International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders taking place in Vienna, Austria April 1-5 2025.The poster details the demographics and biomarker status of patients at the time of enrollment in the MINDFul Phase II blinded, randomized trial in patients with early AD and biomarkers of inflammation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top